We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
The mission at sano is to bring education and knowledge to everybody, so that they can eat healthly and take control of their own health. The strategy behind Sano to go is to become a leader in the healthy food delivery market.
days to go: Expired investment: Withheld
Yumbles is a leading UK online marketplace for artisan food. It currently connects over 600 independent food makers directly with consumers. The company is targeting the UK’s estimated £10bn+ UK Speciality Food & Drink market, having seen £1m+ sales in the last 12 months resulting in £400k+ revenue.
days to go: Expired investment: £262,080
DABBOUS is a highly successful, Michelin starred, modern fine-dining restaurant and bar in central London. Opened in January 2012 by Ollie Dabbous and Oskar Kinberg, DABBOUS offers innovative style and creative interpretation of modern European cuisine in an industrial setting.  
days to go: Expired investment: £3,124,165
Swing has pioneered an IoT-connected micro-gym, the Swing Box, equipped with integrated free weights suitable for outdoor use. This innovative gym solution includes adjustable backrests and various dumbbells and kettlebells, catering to users of all fitness levels. Users can conveniently locate, reserve, and unlock the Swing Box using any smartphone, aiming to combat physical inactivity, which contributes to a significant number of deaths and costs the UK £7.4 billion annually. Swing's solution addresses the barriers of affordability, accessibility, and time in exercise by providing on-demand, free-access outdoor micro-gyms in communal parks and green spaces. With over 90% of UK residents within a 10-minute walk of public parks and only 32% meeting NHS guidelines for muscle-strength activity, Swing aims to lease these boxes to grant public access with leaseholders paying an annual fee of £2500 per box, covering maintenance and operations.
days to go: Expired investment: £287,590
QuickQueue enables users to order-ahead for food & drinks in quick-service restaurants - with orders paid-for, ready to collect upon arrival and loyalty points automatically saved on their phone. With QuickQueue, users save time and money, while retailers increase profits by intensifying customer loyalty and gaining unparalleled customer analytics.
days to go: Expired investment: £283,124
Almost 75% of beer sales in 2017 consisted of lager and estimated to be worth £19.5bn. Utopian has spent months researching the market and is now planning to build a 3500L brew house with vessels able to produce more than 8,000 Hectolitres per year, with further expansion already in the pipeline.
days to go: Expired investment: £426,960
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph